IgM Fc receptor in CLL

CLL 中的 IgM Fc 受体

• 批准号: 8431808
• 负责人: Hiromi Kubagawa
• 金额: $ 18.31万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-02-20 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8431808
• 关键词: Antibodies; Antigen Receptors; Antigen-Antibody Complex; Antigens; Apoptosis; Apoptotic; Autoantibodies; B-Lymphocytes; Binding; Biochemical; Biological Assay; Biology; Blocking Antibodies; Cell Survival; Cell physiology; Cell surface; Cells; Cessation of life; Characteristics; Chronic; Chronic Lymphocytic Leukemia; Clinical; Cloning; Complementary DNA; Conflict (Psychology); Confounding Factors (Epidemiology); Cytoplasmic Tail; Data; Databases; Development; Diagnostic; Disease; Effectiveness; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Fc Receptor; Fluorochrome; Fostering; Future; Generations; Genes; Glycoproteins; Goals; Health; Hematologic Neoplasms; IgM Fc receptor; Immune; Immunoglobulin G; Immunoglobulin M; Individual; Knowledge; Label; Lead; Leukemic Cell; Ligation; Literature; Mediating; Membrane; Mission; Monoclonal Antibodies; Mus; Mutation; Nature; Outcome; Pathogenesis; Patient Care; Patients; Pilot Projects; Play; Preventive Intervention; Prognostic Marker; Public Health; Publishing; RNA Splicing; Receptors, Antigen, B-Cell; Regulation; Research; Research Personnel; Resistance; Role; Serum; Signal Transduction; Surface; T-Cell Activation; T-Lymphocyte; TNFRSF6 gene; Testing; Therapeutic; Therapeutic Intervention; Time; Transcript; United States National Institutes of Health; Work; anti-IgM; base; cell type; clinically relevant; clinically significant; cost effective; improved; innovation; leukemia; novel; outcome forecast; prognostic; receptor; receptor expression; therapeutic target; tool; variable region gene

DESCRIPTION (provided by applicant): The long-term goals of our studies are to develop an improved understanding of the disease sub-sets in chronic lymphocytic leukemia (CLL) and thereby propel the development of improved prognostic tools and identification of therapeutic targets. The objectives of this application are to determine the clinical relevance of the enhanced expression of the Fc receptor for IgM (Fc¿R) by CLL B cells and to explore the role of Fc¿R signaling in promoting CLL-cell survival. The over-expression of Fc¿R by CLL cells has been suspected for some time, but the lack of direct assays has been a major barrier to unambiguous analysis. Our recent functional cloning of the FCMR cDNA and subsequent generation of receptor-specific mAbs are enabling rapid clarification of the expression of the Fc¿R and its functional roles. Based on our preliminary data and the available literature concerning CLL, we have formulated the central hypothesis that: the enhanced Fc¿R expression by CLL B cells is a result of chronic antigenic stimulation and the ensuing IgM/antigen immune complexes lead to co-ligation of Fc¿R and the IgM B cell receptor (BCR) on CLL cells, thereby providing a survival signal. Our approach is in Aim 1, to define the potential clinical relevance of the enhanced expression of both membrane-bound and soluble forms of Fc¿R in patients with CLL. The working hypotheses are: (i) Both cell surface and serum levels of Fc¿R predict the mutation status of the Ig heavy chain V region gene and the clinical progression in CLL; and (ii) The soluble form of Fc¿R detected in CLL patients' sera, which is encoded by an alternatively spliced transcript, is produced by CLL B cells and modulates CLL B-cell function as a decoy receptor or by interacting with the membrane IgM. The cell surface and serum levels of Fc¿R in patients with CLL and normal individuals will be quantified using a unique panel of monoclonal antibodies for flow cytometric analyses and a newly developed enzyme-linked immunosorbent assay. In parallel, transcript levels will be analyzed using real time quantitative PCR. In Aim 2, the role of Fc¿R in survival of CLL B cells will be explored. The effects of co-ligation of Fc¿R and surface IgM on CLL cell survival will be determined, as well as whether the highly-expressed Fc¿R interacts with membrane IgM on the same CLL cells. The study is technically innovative as it utilizes IgM antibodies for cross-linkage of the B-cell receptor and the Fc¿R along with Fc¿R -blocking antibodies, and is conceptually innovative as it is expected to provide the first demonstration of a survival function of Fc¿R for CLL B cells as a consequence of interaction with IgM/antigen immune complexes. The clinical significance lies in the expected definition of surface and soluble Fc¿R as reliable markers for predicting the prognosis and disease activity of CLL, which will form the basis for subsequent rapid development of a robust cost-effective prognostic test for CLL patients. Evidence supporting the central hypothesis will greatly improve the understanding of the pathogenesis of CLL and justify the future exploration of the effectiveness of targeting Fc¿R in CLL.

描述（由申请人提供）：我们研究的长期目标是提高对慢性淋巴细胞白血病（CLL）疾病亚组的理解，从而推动改进预后工具的开发和治疗靶点的鉴定。本申请的目的是确定CLL B细胞的IgM Fc受体（Fc <$R）表达增强的临床相关性，并探索Fc <$R信号传导在促进CLL细胞存活中的作用。Fc的过度表达一段时间以来，人们一直怀疑CLL细胞的R，但缺乏直接测定一直是明确分析的主要障碍。我们最近的FCMR cDNA的功能性克隆和随后产生的受体特异性单克隆抗体能够快速澄清Fc受体的表达及其功能作用。基于我们的初步数据和有关CLL的现有文献，我们制定了中心假设：CLL B细胞的Fc <$R表达增强是慢性抗原刺激的结果，随后的IgM/抗原免疫复合物导致Fc <$R和CLL细胞上的IgM B细胞受体（BCR）共连接，从而提供了生存信号。我们的方法是在目标1中，定义CLL患者中膜结合形式和可溶性形式的Fc ² R表达增强的潜在临床相关性。工作假设是：（i）细胞表面和血清中的Fc <$R水平均可预测IG重链V区基因的突变状态和CLL的临床进展;（ii）在CLL患者血清中检测到的Fc <$R的可溶性形式由可变剪接转录物编码，由CLL B细胞产生，并作为诱饵受体或通过与膜IgM相互作用调节CLL B细胞功能。将使用一组独特的单克隆抗体进行流式细胞术分析和一种新开发的酶联免疫吸附试验，对CLL患者和正常个体的细胞表面和血清Fc？R水平进行定量。同时，使用真实的时间定量PCR分析转录水平。在目标2中，将探索Fc受体在CLL B细胞存活中的作用。将确定Fc R和表面IgM的共连接对CLL细胞存活的影响，以及高表达的Fc R是否与相同CLL细胞上的膜IgM相互作用。该研究在技术上是创新的，因为它利用IgM抗体与Fc受体阻断抗体沿着交联B细胞受体和Fc受体，并且在概念上是创新的，因为它有望首次证明Fc受体与IgM/抗原免疫复合物相互作用对CLL B细胞的存活功能。临床意义在于表面和可溶性Fc受体作为预测CLL预后和疾病活动性的可靠标志物的预期定义，这将为随后快速开发用于CLL患者的稳健的成本效益预后测试奠定基础。支持中心假设的证据将大大提高对CLL发病机制的理解，并证明未来探索靶向Fc受体在CLL中的有效性。